Tag: Catabasis Pharmaceuticals

January 8, 2020

Catabasis to Evaluate Muscular Dystrophy Treatment

Catabasis has entered into a partnership for a Phase 2 trial of a novel NF-kB inhibitor that treats a form...
June 21, 2019

Catabasis Pharmaceuticals Presents Preclinical Data of Edasalonexent

Catabasis Pharmaceuticals (NASDAQ:CATB) has announced preclinical data for its edasalonexent in Phase 2 development to treat Duchenne musclar dystrophy (DMD)....